Trial Profile
Early Access of TMC207 in Combination With Other Anti-Tuberculosis (TB) Drugs in Subjects With Extensively Drug Resistant (XDR) or Pre-XDR Pulmonary Tuberculosis (TB)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Feb 2017
Price :
$35
*
At a glance
- Drugs Bedaquiline (Primary) ; Antibacterials
- Indications Pulmonary tuberculosis
- Focus Expanded access; Therapeutic Use
- Sponsors Janssen Infectious Diseases BVBA
- 08 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Aug 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 17 Mar 2012 Planned end date changed from 1 Oct 2014 to 16 Nov 2016 as reported by European Clinical Trials Database record.